Compile Data Set for Download or QSAR
Report error Found 97 for UniProtKB: P12830
TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682693(US20240208940, Example 37)
Affinity DataKi: <2.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682693(US20240208940, Example 37)
Affinity DataIC50: 2.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682700(US20240208940, Example 44)
Affinity DataKi: <2.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682700(US20240208940, Example 44)
Affinity DataIC50: 2.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682673(US20240208940, Example 17)
Affinity DataKi: <2.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682673(US20240208940, Example 17)
Affinity DataIC50: 2.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682701(US20240208940, Example 45)
Affinity DataKi: <4.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682701(US20240208940, Example 45)
Affinity DataIC50: 4.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682687(US20240208940, Example 31)
Affinity DataKi: <5.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682687(US20240208940, Example 31)
Affinity DataIC50: 5.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682686(US20240208940, Example 30)
Affinity DataKi: <5.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682686(US20240208940, Example 30)
Affinity DataIC50: 5.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682675(US20240208940, Example 19)
Affinity DataKi: <5.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682691(US20240208940, Example 35)
Affinity DataKi: <5.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682675(US20240208940, Example 19)
Affinity DataIC50: 5.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682691(US20240208940, Example 35)
Affinity DataIC50: 5.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682692(US20240208940, Example 36)
Affinity DataKi: <5.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682692(US20240208940, Example 36)
Affinity DataIC50: 5.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682667(US20240208940, Example 11)
Affinity DataKi: <5.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682667(US20240208940, Example 11)
Affinity DataIC50: 5.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682668(US20240208940, Example 12)
Affinity DataKi: <5.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682668(US20240208940, Example 12)
Affinity DataIC50: 5.00E+3nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682688(US20240208940, Example 32)
Affinity DataKi: <1.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682688(US20240208940, Example 32)
Affinity DataIC50: 1.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682669(US20240208940, Example 13)
Affinity DataKi: <1.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682669(US20240208940, Example 13)
Affinity DataIC50: 1.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682670(US20240208940, Example 14)
Affinity DataKi: <1.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682670(US20240208940, Example 14)
Affinity DataIC50: 1.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682689(US20240208940, Example 33)
Affinity DataKi: <1.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682689(US20240208940, Example 33)
Affinity DataIC50: 1.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682690(US20240208940, Example 34)
Affinity DataKi: <1.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682690(US20240208940, Example 34)
Affinity DataIC50: 1.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCadherin-1 [819-873]/Catenin beta-1 [138-686](Human)
University of Utah

US Patent
LigandPNGBDBM50094484(CHEMBL2323033 | CHEBI:3556 | US9284299, CGP049090 ...)
Affinity DataKi:  1.17E+4nM ΔG°:  -28.2kJ/molepH: 7.4 T: 2°CAssay Description:Experiments were performed in white opaque 384-well plates from PerkinElmer (Waltham, Mass.), and the samples were read on a Synergy 2 plate reader (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2017
Entry Details
US Patent

TargetCadherin-1 [819-873]/Catenin beta-1 [138-686](Human)
University of Utah

US Patent
LigandPNGBDBM213748(US9284299, PKF115-584 | US9738628, Compound PKF115...)
Affinity DataKi:  1.30E+4nM ΔG°:  -27.9kJ/moleT: 2°CAssay Description:Experiments were performed in 96-well Microfluor 2 black plates (Waltham, Mass.), and the samples were read by a Synergy 2 plate reader (Biotek, Wino...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2017
Entry Details
US Patent

TargetCadherin-1 [819-873]/Catenin beta-1 [138-686](Human)
University of Utah

US Patent
LigandPNGBDBM32102(cid_66541 | 1,6-dimethylpyrimido[5,4-e][1,2,4]tria...)
Affinity DataKi:  1.33E+4nM ΔG°:  -27.8kJ/moleT: 2°CAssay Description:Experiments were performed in 96-well Microfluor 2 black plates (Waltham, Mass.), and the samples were read by a Synergy 2 plate reader (Biotek, Wino...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2017
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682695(US20240208940, Example 39)
Affinity DataKi:  1.40E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCadherin-1 [819-873]/Catenin beta-1 [138-686](Human)
University of Utah

US Patent
LigandPNGBDBM50094484(CHEMBL2323033 | CHEBI:3556 | US9284299, CGP049090 ...)
Affinity DataKi:  1.44E+4nM ΔG°:  -27.6kJ/moleT: 2°CAssay Description:Experiments were performed in 96-well Microfluor 2 black plates (Waltham, Mass.), and the samples were read by a Synergy 2 plate reader (Biotek, Wino...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2017
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682695(US20240208940, Example 39)
Affinity DataIC50: 1.70E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCadherin-1 [819-873]/Catenin beta-1 [138-686](Human)
University of Utah

US Patent
LigandPNGBDBM32102(cid_66541 | 1,6-dimethylpyrimido[5,4-e][1,2,4]tria...)
Affinity DataKi:  1.99E+4nM ΔG°:  -26.8kJ/molepH: 7.4 T: 2°CAssay Description:Experiments were performed in white opaque 384-well plates from PerkinElmer (Waltham, Mass.), and the samples were read on a Synergy 2 plate reader (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2017
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682671(US20240208940, Example 15)
Affinity DataKi: <2.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682671(US20240208940, Example 15)
Affinity DataIC50: 2.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682674(US20240208940, Example 18)
Affinity DataKi: <2.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682674(US20240208940, Example 18)
Affinity DataIC50: 2.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682694(US20240208940, Example 38)
Affinity DataKi: <2.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682694(US20240208940, Example 38)
Affinity DataIC50: 2.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682684(US20240208940, Example 28)
Affinity DataKi: <2.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682684(US20240208940, Example 28)
Affinity DataIC50: 2.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682665(US20240208940, Example 9)
Affinity DataKi: <2.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682697(US20240208940, Example 41)
Affinity DataKi: <2.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetCatenin beta -1 [E155A]/B-Cell CLL/Lymphoma 9 Protein [350-375]/Cadherin-1 [824-877](Homo sapiens (Human))
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM682665(US20240208940, Example 9)
Affinity DataIC50: 2.00E+4nMAssay Description:Full-length wild-type β-catenin (residues 1-781), full-length β-catenin D145 Å, or full-length β-catenin E155A were cloned into ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

Displayed 1 to 50 (of 97 total ) | Next | Last >>
Jump to: